Effectiveness of maternal pertussis vaccination in England: an observational study
- PMID: 25037990
- DOI: 10.1016/S0140-6736(14)60686-3
Effectiveness of maternal pertussis vaccination in England: an observational study
Abstract
Background: In October, 2012, a pertussis vaccination programme for pregnant women was introduced in response to an outbreak across England. We aimed to assess the vaccine effectiveness and the overall effect of the vaccine programme in preventing pertussis in infants.
Methods: We undertook an analysis of laboratory-confirmed cases and hospital admissions for pertussis in infants between Jan 1, 2008, and Sept 30, 2013, using data submitted to Public Health England as part of its enhanced surveillance of pertussis in England, to investigate the effect of the vaccination programme. We calculated vaccine effectiveness by comparing vaccination status for mothers in confirmed cases with estimates of vaccine coverage for the national population of pregnant women, based on data from the Clinical Practice Research Datalink.
Findings: The monthly total of confirmed cases peaked in October, 2012 (1565 cases), and subsequently fell across all age groups. For the first 9 months of 2013 compared with the same period in 2012, the greatest proportionate fall in confirmed cases (328 cases in 2012 vs 72 cases in 2013, -78%, 95% CI -72 to -83) and in hospitalisation admissions (440 admissions in 2012 vs 140 admissions in 2013, -68%, -61 to -74) occurred in infants younger than 3 months, although the incidence remained highest in this age group. Infants younger than 3 months were also the only age group in which there were fewer cases in 2013 than in 2011 (118 cases in 2011 vs 72 cases in 2013), before the resurgence. 26?684 women included in the Clinical Practice Research Datalink had a livebirth between Oct 1, 2012 and Sept 3, 2013; the average vaccine coverage before delivery based on this cohort was 64%. Vaccine effectiveness based on 82 confirmed cases in infants born from Oct 1, 2012, and younger than 3 months at onset was 91% (95% CI 84 to 95). Vaccine effectiveness was 90% (95% CI 82 to 95) when the analysis was restricted to cases in children younger than 2 months.
Interpretation: Our assessment of the programme of pertussis vaccination in pregnancy in England is consistent with high vaccine effectiveness. This effectiveness probably results from protection of infants by both passive antibodies and reduced maternal exposure, and will provide valuable information to international policy makers.
Funding: Public Health England.
Comment in
-
Pertussis vaccine in pregnancy--first dose for every infant?Lancet. 2014 Oct 25;384(9953):1484-6. doi: 10.1016/S0140-6736(14)60977-6. Epub 2014 Jul 15. Lancet. 2014. PMID: 25037989 No abstract available.
Similar articles
-
Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance.Vaccine. 2012 May 2;30(21):3239-47. doi: 10.1016/j.vaccine.2011.10.089. Epub 2011 Nov 15. Vaccine. 2012. PMID: 22094282
-
Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England.Arch Dis Child. 2018 Mar;103(3):224-229. doi: 10.1136/archdischild-2016-311802. Epub 2017 Aug 16. Arch Dis Child. 2018. PMID: 28814424
-
A case-control study to assess the effectiveness of pertussis vaccination during pregnancy on newborns, Valencian community, Spain, 1 March 2015 to 29 February 2016.Euro Surveill. 2017 Jun 1;22(22):30545. doi: 10.2807/1560-7917.ES.2017.22.22.30545. Euro Surveill. 2017. PMID: 28598324 Free PMC article.
-
Experience and challenges on influenza and pertussis vaccination in pregnant women.Hum Vaccin Immunother. 2018;14(9):2183-2188. doi: 10.1080/21645515.2018.1483810. Epub 2018 Jul 24. Hum Vaccin Immunother. 2018. PMID: 30024822 Free PMC article. Review.
-
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.Vaccine. 2013 Oct 25;31(45):5178-91. doi: 10.1016/j.vaccine.2013.08.034. Epub 2013 Aug 28. Vaccine. 2013. PMID: 23994021 Review.
Cited by
-
Pertussis Epidemiology in Children: The Role of Maternal Immunization.Vaccines (Basel). 2024 Sep 9;12(9):1030. doi: 10.3390/vaccines12091030. Vaccines (Basel). 2024. PMID: 39340060 Free PMC article. Review.
-
Global tendency and frontiers of research on pertussis from 2000 to 2023: A bibliometric and visual analysis.Hum Vaccin Immunother. 2024 Dec 31;20(1):2392334. doi: 10.1080/21645515.2024.2392334. Epub 2024 Sep 5. Hum Vaccin Immunother. 2024. PMID: 39238254 Free PMC article.
-
Insights into maternal pertussis vaccination counselling: a qualitative study on perspectives and experiences among midwives and gynaecologists in the Netherlands.BMC Infect Dis. 2024 Sep 2;24(1):903. doi: 10.1186/s12879-024-09681-7. BMC Infect Dis. 2024. PMID: 39223488 Free PMC article.
-
Promotion and COVID-19 lockdown increase uptake of funded maternal pertussis vaccination in pharmacy: A mixed methods study.PLoS One. 2024 Aug 29;19(8):e0307971. doi: 10.1371/journal.pone.0307971. eCollection 2024. PLoS One. 2024. PMID: 39208314 Free PMC article.
-
Transfer of Respiratory Syncytial Virus Prefusion F Protein Antibody in Low Birthweight Infants.Open Forum Infect Dis. 2024 Jul 22;11(7):ofae314. doi: 10.1093/ofid/ofae314. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39040482 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
